pyrithione zinc 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4248 13463-41-7

Description:

MoleculeDescription

Synonyms:

  • pyrithione zinc
  • zinc pyrithione
dimer of two pyrithione molecules bound by zinc; ingredient of commercial anti-dandruff shampoos; Do not confuse zinc pyrithione with Raman spectrum probe dye known as zincon; antifungal and antibacterial
  • Molecular weight: 317.69
  • Formula: C10H8N2O2S2Zn
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 521.42 13.30 191 21477 13631 63453723
Creatinine renal clearance decreased 494.22 13.30 192 21476 16116 63451238
Blood calcium decreased 429.48 13.30 200 21468 26251 63441103
Orthostatic hypotension 364.66 13.30 198 21470 35962 63431392
Sedation 359.72 13.30 201 21467 38608 63428746
Cognitive disorder 323.59 13.30 214 21454 55601 63411753
Balance disorder 273.36 13.30 228 21440 84194 63383160
Depressed level of consciousness 264.18 13.30 197 21471 61881 63405473
Mobility decreased 215.54 13.30 235 21433 120924 63346430
Constipation 203.54 13.30 312 21356 224631 63242723
COVID-19 119.55 13.30 169 21499 112934 63354420
Fall 98.84 13.30 326 21342 392008 63075346
Hypotension 74.40 13.30 233 21435 272371 63194983
Toxicity to various agents 59.03 13.30 202 21466 247048 63220306
Pain 57.48 13.30 440 21228 740188 62727166
Contraindicated product administered 53.29 13.30 6 21662 217642 63249712
Illness 49.84 13.30 72 21596 48987 63418367
Pulmonary pain 49.28 13.30 24 21644 3466 63463888
Synovitis 48.80 13.30 4 21664 186914 63280440
Necrosis ischaemic 44.31 13.30 15 21653 845 63466509
Systemic lupus erythematosus 43.76 13.30 9 21659 208909 63258445
Multiple drug therapy 42.45 13.30 22 21646 3624 63463730
Salpingo-oophorectomy unilateral 40.08 13.30 14 21654 867 63466487
Maternal exposure during pregnancy 37.67 13.30 14 21654 220048 63247306
Aplastic anaemia 37.61 13.30 29 21639 9540 63457814
Amyloid arthropathy 37.46 13.30 12 21656 568 63466786
Glossodynia 36.86 13.30 8 21660 178868 63288486
Drug ineffective 36.43 13.30 209 21459 1044556 62422798
Beta haemolytic streptococcal infection 34.97 13.30 16 21652 2009 63465345
Pneumonia streptococcal 33.46 13.30 15 21653 1796 63465558
Sinusitis fungal 33.30 13.30 15 21653 1816 63465538
Product dose omission issue 32.49 13.30 162 21506 234151 63233203
Skin odour abnormal 31.42 13.30 14 21654 1652 63465702
Copper deficiency 31.19 13.30 7 21661 81 63467273
Nasal polyps 29.82 13.30 21 21647 6018 63461336
Death 29.16 13.30 52 21616 374329 63093025
Sputum increased 29.09 13.30 15 21653 2444 63464910
Dermatitis atopic 28.81 13.30 25 21643 9699 63457655
Eczema 27.96 13.30 44 21624 32247 63435107
Wound secretion 27.43 13.30 18 21650 4596 63462758
Respiratory symptom 27.38 13.30 16 21652 3331 63464023
Lipoedema 27.02 13.30 8 21660 290 63467064
Arthritis infective 26.27 13.30 20 21648 6458 63460896
Embolism venous 25.60 13.30 15 21653 3139 63464215
Spinal cord disorder 24.92 13.30 11 21657 1270 63466084
White blood cell count decreased 24.32 13.30 103 21565 139001 63328353
Norovirus infection 24.29 13.30 9 21659 661 63466693
Diastolic dysfunction 24.11 13.30 19 21649 6452 63460902
Acquired diaphragmatic eventration 23.74 13.30 8 21660 444 63466910
Rhinocerebral mucormycosis 23.52 13.30 8 21660 457 63466897
Infrapatellar fat pad inflammation 21.79 13.30 6 21662 167 63467187
Acute kidney injury 21.02 13.30 36 21632 263379 63203975
Discomfort 20.80 13.30 16 21652 167358 63299996
Procedural complication 20.33 13.30 16 21652 5423 63461931
Fistula discharge 20.03 13.30 9 21659 1084 63466270
Rheumatoid arthritis 19.97 13.30 35 21633 253784 63213570
Wound 19.79 13.30 16 21652 163247 63304107
Female genital tract fistula 19.55 13.30 18 21650 7541 63459813
Feeling abnormal 19.42 13.30 101 21567 148291 63319063
Terminal insomnia 19.40 13.30 8 21660 781 63466573
Yellow skin 18.92 13.30 11 21657 2269 63465085
Infusion site extravasation 18.09 13.30 20 21648 10406 63456948
Cardiac arrest 17.39 13.30 5 21663 92540 63374814
Emphysema 17.31 13.30 20 21648 10918 63456436
Heart rate variability increased 17.12 13.30 4 21664 56 63467298
Eyelid margin crusting 17.05 13.30 8 21660 1064 63466290
Treatment failure 17.00 13.30 26 21642 199017 63268337
Gastrointestinal candidiasis 16.69 13.30 5 21663 189 63467165
Haemorrhagic diathesis 16.52 13.30 13 21655 4402 63462952
Chondropathy 16.23 13.30 10 21658 2290 63465064
Disease recurrence 16.22 13.30 32 21636 27998 63439356
Effusion 16.17 13.30 9 21659 1709 63465645
Hysterectomy 16.10 13.30 18 21650 9481 63457873
Seasonal allergy 16.04 13.30 27 21641 20923 63446431
Candida infection 15.96 13.30 32 21636 28319 63439035
Fear of falling 15.77 13.30 6 21662 474 63466880
Endometrial cancer 15.43 13.30 11 21657 3214 63464140
Product use in unapproved indication 15.23 13.30 109 21559 178971 63288383
Chest discomfort 15.19 13.30 76 21592 109893 63357461
Product use issue 15.10 13.30 33 21635 220487 63246867
Blood smear test abnormal 14.90 13.30 4 21664 101 63467253
Confusional state 14.88 13.30 37 21631 236343 63231011
Sneezing 14.64 13.30 24 21644 18194 63449160
Joint swelling 14.53 13.30 60 21608 327606 63139748
Thinking abnormal 14.45 13.30 18 21650 10625 63456729
Ocular icterus 14.19 13.30 11 21657 3645 63463709
Cough 13.95 13.30 157 21511 292586 63174768
Product dose omission in error 13.90 13.30 15 21653 7597 63459757
General physical health deterioration 13.90 13.30 30 21638 201372 63265982
Multiple allergies 13.64 13.30 20 21648 13782 63453572
Oral pain 13.60 13.30 30 21638 28364 63438990
Fungal infection 13.40 13.30 35 21633 36839 63430515

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Off label use 78.37 15.01 236 7500 419288 34529907
Rhinocerebral mucormycosis 56.87 15.01 15 7721 553 34948642
COVID-19 54.48 15.01 76 7660 77474 34871721
Radiation inflammation 41.46 15.01 13 7723 892 34948303
Pulmonary pain 37.61 15.01 13 7723 1211 34947984
Product dose omission issue 33.99 15.01 79 7657 119632 34829563
Fatigue 25.37 15.01 154 7582 370499 34578696
Aplastic anaemia 22.41 15.01 18 7718 9698 34939497
Sinusitis 18.49 15.01 33 7703 41369 34907826
Vascular device infection 17.15 15.01 11 7725 4174 34945021
Metal poisoning 16.97 15.01 4 7732 92 34949103
Arthropathy 16.85 15.01 25 7711 26882 34922313
Toxicity to various agents 16.72 15.01 12 7724 200350 34748845
Copper deficiency 16.14 15.01 3 7733 20 34949175
Illness 15.53 15.01 17 7719 13512 34935683

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sedation complication 535.81 12.70 195 23864 15474 79704855
Creatinine renal clearance decreased 502.74 12.70 196 23863 18806 79701523
Blood calcium decreased 436.03 12.70 206 23853 31613 79688716
Sedation 338.69 12.70 205 23854 51690 79668639
Orthostatic hypotension 321.26 12.70 204 23855 55960 79664369
Cognitive disorder 315.36 12.70 219 23840 69707 79650622
Balance disorder 260.29 12.70 225 23834 98632 79621697
Mobility decreased 232.44 12.70 232 23827 121943 79598386
Depressed level of consciousness 212.94 12.70 199 23860 96453 79623876
Constipation 182.66 12.70 315 23744 282735 79437594
COVID-19 146.98 12.70 208 23851 157466 79562863
Pain 88.18 12.70 432 23627 703370 79016959
Pulmonary pain 86.89 12.70 37 24022 4436 79715893
Fall 80.37 12.70 325 23734 487304 79233025
Rhinocerebral mucormycosis 75.71 12.70 23 24036 1035 79719294
Hypotension 53.31 12.70 268 23791 440049 79280280
Product dose omission issue 53.26 12.70 180 23879 247357 79472972
Aplastic anaemia 49.57 12.70 42 24017 17863 79702466
Off label use 48.10 12.70 450 23609 906765 78813564
Illness 47.21 12.70 64 23995 46447 79673882
Copper deficiency 44.30 12.70 10 24049 136 79720193
Multiple drug therapy 42.68 12.70 22 24037 4056 79716273
Necrosis ischaemic 42.64 12.70 15 24044 1075 79719254
Salpingo-oophorectomy unilateral 42.52 12.70 14 24045 820 79719509
Nasal polyps 40.31 12.70 26 24033 7301 79713028
Amyloid arthropathy 38.91 12.70 12 24047 568 79719761
Radiation inflammation 37.50 12.70 13 24046 892 79719437
Synovitis 34.36 12.70 3 24056 150731 79569598
Beta haemolytic streptococcal infection 33.13 12.70 15 24044 2082 79718247
Skin odour abnormal 32.83 12.70 15 24044 2126 79718203
Sinusitis fungal 31.35 12.70 15 24044 2359 79717970
Acute kidney injury 29.65 12.70 71 23988 519333 79200996
Pneumonia streptococcal 29.28 12.70 15 24044 2730 79717599
Drug ineffective 29.16 12.70 199 23860 1080714 78639615
Contraindicated product administered 27.16 12.70 7 24052 157531 79562798
Sputum increased 26.94 12.70 17 24042 4596 79715733
Acquired diaphragmatic eventration 25.53 12.70 9 24050 649 79719680
Female genital tract fistula 25.23 12.70 18 24041 5957 79714372
Toxicity to various agents 25.22 12.70 215 23844 421325 79299004
Arthritis infective 24.13 12.70 20 24039 8251 79712078
Respiratory symptom 23.92 12.70 16 24043 4775 79715554
Embolism venous 23.21 12.70 15 24044 4224 79716105
Infrapatellar fat pad inflammation 22.52 12.70 6 24053 167 79720162
Wound secretion 22.42 12.70 17 24042 6171 79714158
Eczema 21.86 12.70 42 24017 40776 79679553
Systemic lupus erythematosus 21.63 12.70 5 24054 121144 79599185
Pericarditis 21.42 12.70 3 24056 104233 79616096
Norovirus infection 21.24 12.70 8 24051 696 79719633
Oral pain 21.22 12.70 36 24023 31762 79688567
Lipoedema 21.04 12.70 6 24053 216 79720113
Coma 20.44 12.70 3 24056 100646 79619683
Hysterectomy 20.05 12.70 16 24043 6256 79714073
Intentional overdose 19.67 12.70 4 24055 105956 79614373
Taste disorder 19.54 12.70 24 24035 15799 79704530
Diastolic dysfunction 19.54 12.70 20 24039 10791 79709538
Chest discomfort 19.52 12.70 88 23971 137956 79582373
Fistula discharge 19.15 12.70 9 24050 1359 79718970
Sinusitis 18.86 12.70 112 23947 195389 79524940
Infusion site extravasation 18.81 12.70 19 24040 10089 79710240
Disease recurrence 18.46 12.70 41 24018 44068 79676261
Death 17.97 12.70 99 23960 566415 79153914
Heart rate variability increased 17.55 12.70 4 24055 57 79720272
Seasonal allergy 17.29 12.70 23 24036 16383 79703946
Feeling abnormal 17.19 12.70 94 23965 159105 79561224
Cardiac failure 17.11 12.70 13 24046 154829 79565500
Maternal exposure during pregnancy 17.06 12.70 10 24049 136528 79583801
Terminal insomnia 17.02 12.70 8 24051 1209 79719120
White blood cell count decreased 16.98 12.70 106 23953 188182 79532147
Spinal cord disorder 16.65 12.70 9 24050 1826 79718503
Chondropathy 16.56 12.70 10 24049 2502 79717827
General physical health deterioration 16.17 12.70 37 24022 275201 79445128
Sinus disorder 15.74 12.70 26 24033 22438 79697891
Endometrial cancer 15.54 12.70 9 24050 2085 79718244
Sneezing 15.46 12.70 24 24035 19659 79700670
Dermatitis atopic 15.34 12.70 17 24042 10039 79710290
Fatigue 15.16 12.70 377 23682 929350 78790979
Opportunistic infection 15.08 12.70 10 24049 2940 79717389
Effusion 15.08 12.70 9 24050 2205 79718124
Eyelid margin crusting 14.93 12.70 7 24052 1052 79719277
SARS-CoV-2 test positive 14.84 12.70 18 24041 11698 79708631
Multiple allergies 14.79 12.70 17 24042 10443 79709886
Drug interaction 14.59 12.70 70 23989 415113 79305216
Emphysema 14.41 12.70 21 24038 16279 79704050
Fear of falling 14.33 12.70 6 24053 689 79719640
Rhinorrhoea 14.33 12.70 53 24006 76021 79644308
Angioedema 13.85 12.70 3 24056 76032 79644297
Hiatus hernia 13.75 12.70 25 24034 23287 79697042
Tenderness 13.49 12.70 25 24034 23617 79696712
Gastrointestinal candidiasis 13.34 12.70 5 24054 429 79719900
Myocardial infarction 13.20 12.70 22 24037 184107 79536222
Sleep apnoea syndrome 13.17 12.70 32 24027 36446 79683883
Headache 13.10 12.70 273 23786 653499 79066830
Procedural complication 13.05 12.70 14 24045 7969 79712360
Neutropenia 12.95 12.70 44 24015 287666 79432663
Dysphoria 12.89 12.70 11 24048 4723 79715606
Spleen atrophy 12.78 12.70 3 24056 49 79720280

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AX12 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Other dermatologicals
MeSH PA D003879 Dermatologic Agents
MeSH PA D007641 Keratolytic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Seborrheic dermatitis indication 50563003 DOID:8741
Pityriasis simplex indication 200767005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Carbonic anhydrase 4 Enzyme Ki 5.21 CHEMBL
Potassium voltage-gated channel subfamily KQT member 2 Ion channel ACTIVATOR EC50 5.80 IUPHAR
Carbonic anhydrase 9 Enzyme Ki 5.76 CHEMBL
Carbonic anhydrase 12 Enzyme Ki 5.27 CHEMBL
Potassium voltage-gated channel subfamily KQT member 1 Ion channel ACTIVATOR EC50 5 IUPHAR
Carbonic anhydrase 5A, mitochondrial Enzyme Ki 5.29 CHEMBL
Carbonic anhydrase 5B, mitochondrial Enzyme Ki 5.45 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.11 CHEMBL
Potassium voltage-gated channel subfamily KQT member 5 Ion channel ACTIVATOR EC50 5 IUPHAR
Carbonic anhydrase 3 Enzyme Ki 5.79 CHEMBL
Carbonic anhydrase 6 Enzyme Ki 5.62 CHEMBL
Carbonic anhydrase 14 Enzyme Ki 5.54 CHEMBL
Potassium voltage-gated channel subfamily KQT member 4 Ion channel ACTIVATOR EC50 5 IUPHAR
Carbonic anhydrase 13 Enzyme Ki 5.38 CHEMBL

External reference:

IDSource
4020508 VUID
N0000179286 NUI
D01938 KEGG_DRUG
4019187 VANDF
4020508 VANDF
C0078792 UMLSCUI
CHEBI:32076 CHEBI
CHEMBL3392049 ChEMBL_ID
CHEMBL1200471 ChEMBL_ID
C010423 MESH_SUPPLEMENTAL_RECORD_UI
2597 IUPHAR_LIGAND_ID
2295 INN_ID
R953O2RHZ5 UNII
3729132 PUBCHEM_CID
39952 RXNORM
4999 MMSL
5397 MMSL
002961 NDDF
255954005 SNOMEDCT_US
411297004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
DHS ZINC HUMAN OTC DRUG LABEL 1 0096-0735 SHAMPOO 20 mg TOPICAL OTC monograph final 8 sections
DHS ZINC HUMAN OTC DRUG LABEL 1 0096-0735 SHAMPOO 20 mg TOPICAL OTC monograph final 8 sections
Dandruff HUMAN OTC DRUG LABEL 1 0363-0253 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 0363-0253 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 0363-0253 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dry Scalp Care HUMAN OTC DRUG LABEL 1 0363-0688 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dry Scalp Care HUMAN OTC DRUG LABEL 1 0363-0688 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
2 in 1 Dandruff HUMAN OTC DRUG LABEL 1 0363-0755 SHAMPOO 10 mg TOPICAL OTC monograph final 13 sections
2 in 1 Dandruff HUMAN OTC DRUG LABEL 1 0363-0755 SHAMPOO 10 mg TOPICAL OTC monograph final 13 sections
2 in 1 Dandruff HUMAN OTC DRUG LABEL 1 0363-0755 SHAMPOO 10 mg TOPICAL OTC monograph final 13 sections
Walgreens Dandruff Itchy Dry Scalp Defense Anti-dandruff HUMAN OTC DRUG LABEL 1 0363-4138 SHAMPOO 10 mg TOPICAL OTC monograph final 13 sections
Walgreens Dandruff Conditioner 2 in 1 Itchy Scalp Anti-dandruff HUMAN OTC DRUG LABEL 1 0363-4288 SHAMPOO 10 mg TOPICAL OTC monograph final 13 sections
Walgreens Dandruff Conditioner 2 in 1 Itchy Scalp Anti-dandruff HUMAN OTC DRUG LABEL 1 0363-4289 SHAMPOO 10 mg TOPICAL OTC MONOGRAPH FINAL 13 sections
Walgreens Dandruff Plus Conditioner 2 in 1 Dry Scalp Anti-dandruff HUMAN OTC DRUG LABEL 1 0363-4666 SHAMPOO 10 mg TOPICAL OTC monograph final 13 sections
Walgreens Dandruff Plus Conditioner 2 in 1 Anti-dandruff HUMAN OTC DRUG LABEL 1 0363-4673 SHAMPOO 10 mg TOPICAL OTC MONOGRAPH FINAL 13 sections
Dandruff HUMAN OTC DRUG LABEL 1 0869-0153 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 0869-0153 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 0869-0153 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Satinique Anti Dandruff HUMAN OTC DRUG LABEL 1 10056-006 CREAM 9.50 mg TOPICAL OTC monograph final 9 sections
Advance Techniques Keep ClearAnti-Dandruff Treatment HUMAN OTC DRUG LABEL 1 10096-0220 LOTION 0.15 mL TOPICAL OTC monograph final 20 sections
Advance Techniques Keep Clear2-in-1 Anti-Dandruff HUMAN OTC DRUG LABEL 1 10096-0221 SHAMPOO 10 mg TOPICAL OTC monograph final 11 sections
American Crew HUMAN OTC DRUG LABEL 1 10967-650 SHAMPOO 1 mg TOPICAL OTC monograph final 8 sections
Dandruff HUMAN OTC DRUG LABEL 1 11344-253 SHAMPOO 10 mg TOPICAL OTC monograph final 11 sections
Dandruff HUMAN OTC DRUG LABEL 1 11344-253 SHAMPOO 10 mg TOPICAL OTC monograph final 11 sections
Fresh Mint Dandruff HUMAN OTC DRUG LABEL 1 11344-309 SHAMPOO 1 kg TOPICAL OTC monograph final 10 sections
2 in 1 Dandruff HUMAN OTC DRUG LABEL 1 11344-311 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
2 in 1 Dandruff HUMAN OTC DRUG LABEL 1 11344-311 SHAMPOO 10 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 11344-443 SHAMPOO 10.40 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 11344-443 SHAMPOO 10.40 mg TOPICAL OTC monograph final 12 sections
Dandruff HUMAN OTC DRUG LABEL 1 11344-475 SHAMPOO 1 mg TOPICAL OTC monograph final 12 sections